{"resourceType":"ValueSet","id":"2.16.840.1.113762.1.4.1142.60","meta":{"versionId":"9","lastUpdated":"2016-09-09T01:00:03.000-04:00"},"url":"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.60","version":"20160909","name":"C2S HIV/AIDS information Sensitivity","status":"active","date":"2016-09-09T01:00:03-04:00","publisher":"SAMHSA Steward","compose":{"include":[{"system":"http://www.ama-assn.org/go/cpt","version":"2021","concept":[{"code":"0575F","display":"HIV RNA control plan of care, documented (HIV)"},{"code":"3292F","display":"HIV testing ordered or documented and reviewed during the first or second prenatal visit (Pre-Cr)"},{"code":"3490F","display":"History of AIDS-defining condition (HIV)"},{"code":"3491F","display":"HIV indeterminate (infants of undetermined HIV status born of HIV-infected mothers) (HIV)"},{"code":"3492F","display":"History of nadir CD4+ cell count \u003c350 cells/mm3 (HIV)"},{"code":"3493F","display":"No history of nadir CD4+ cell count \u003c350 cells/mm3 and no history of AIDS-defining condition (HIV)"},{"code":"3494F","display":"CD4+ cell count \u003c200 cells/mm3 (HIV)"},{"code":"3495F","display":"CD4+ cell count 200 - 499 cells/mm3 (HIV)"},{"code":"3496F","display":"CD4+ cell count \u003e500 cells/mm3 (HIV)"},{"code":"3497F","display":"CD4+ cell percentage \u003c15% (HIV)"},{"code":"3498F","display":"CD4+ cell percentage \u003e15% (HIV)"},{"code":"3500F","display":"CD4+ cell count or CD4+ cell percentage documented as performed (HIV)"},{"code":"3502F","display":"HIV RNA viral load below limits of quantification (HIV)"},{"code":"3503F","display":"HIV RNA viral load not below limits of quantification (HIV)"},{"code":"3510F","display":"Documentation that tuberculosis (TB) screening test performed and results interpreted (HIV) (IBD)"},{"code":"3511F","display":"Chlamydia and gonorrhea screenings documented as performed (HIV)"},{"code":"3512F","display":"Syphilis screening documented as performed (HIV)"},{"code":"3513F","display":"Hepatitis B screening documented as performed (HIV)"},{"code":"3514F","display":"Hepatitis C screening documented as performed (HIV)"},{"code":"3515F","display":"Patient has documented immunity to Hepatitis C (HIV)"},{"code":"4149F","display":"Hepatitis B vaccine injection administered or previously received (HEP-C, HIV) (IBD)"},{"code":"4270F","display":"Patient receiving potent antiretroviral therapy for 6 months or longer (HIV)"},{"code":"4271F","display":"Patient receiving potent antiretroviral therapy for less than 6 months or not receiving potent antiretroviral therapy (HIV)"},{"code":"4274F","display":"Influenza immunization administered or previously received (HIV) (P-ESRD)"},{"code":"4276F","display":"Potent antiretroviral therapy prescribed (HIV)"},{"code":"4279F","display":"Pneumocystis jiroveci pneumonia prophylaxis prescribed (HIV)"},{"code":"4280F","display":"Pneumocystis jiroveci pneumonia prophylaxis prescribed within 3 months of low CD4+ cell count or percentage (HIV)"},{"code":"4290F","display":"Patient screened for injection drug use (HIV)"},{"code":"4293F","display":"Patient screened for high-risk sexual behavior (HIV)"},{"code":"86689","display":"Antibody; HTLV or HIV antibody, confirmatory test (eg, Western Blot)"},{"code":"86701","display":"Antibody; HIV-1"},{"code":"86702","display":"Antibody; HIV-2"},{"code":"86703","display":"Antibody; HIV-1 and HIV-2, single result"},{"code":"87389","display":"Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; HIV-1 antigen(s), with HIV-1 and HIV-2 antibodies, single result"},{"code":"87390","display":"Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; HIV-1"},{"code":"87391","display":"Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; HIV-2"},{"code":"87534","display":"Infectious agent detection by nucleic acid (DNA or RNA); HIV-1, direct probe technique"},{"code":"87535","display":"Infectious agent detection by nucleic acid (DNA or RNA); HIV-1, amplified probe technique, includes reverse transcription when performed"},{"code":"87536","display":"Infectious agent detection by nucleic acid (DNA or RNA); HIV-1, quantification, includes reverse transcription when performed"},{"code":"87537","display":"Infectious agent detection by nucleic acid (DNA or RNA); HIV-2, direct probe technique"},{"code":"87538","display":"Infectious agent detection by nucleic acid (DNA or RNA); HIV-2, amplified probe technique, includes reverse transcription when performed"},{"code":"87539","display":"Infectious agent detection by nucleic acid (DNA or RNA); HIV-2, quantification, includes reverse transcription when performed"},{"code":"87900","display":"Infectious agent drug susceptibility phenotype prediction using regularly updated genotypic bioinformatics"},{"code":"87901","display":"Infectious agent genotype analysis by nucleic acid (DNA or RNA); HIV-1, reverse transcriptase and protease regions"},{"code":"87903","display":"Infectious agent phenotype analysis by nucleic acid (DNA or RNA) with drug resistance tissue culture analysis, HIV 1; first through 10 drugs tested"},{"code":"87904","display":"Infectious agent phenotype analysis by nucleic acid (DNA or RNA) with drug resistance tissue culture analysis, HIV 1; each additional drug tested (List separately in addition to code for primary procedure)"},{"code":"87906","display":"Infectious agent genotype analysis by nucleic acid (DNA or RNA); HIV-1, other region (eg, integrase, fusion)"}]}]},"expansion":{"identifier":"urn:uuid:e430868c-ab4c-4faa-8c43-65aed91b78c0","timestamp":"2022-06-10T05:16:46-04:00","total":47,"offset":0,"parameter":[{"name":"count","valueInteger":1000},{"name":"offset","valueInteger":0}],"contains":[{"system":"http://www.ama-assn.org/go/cpt","version":"2021","code":"0575F","display":"HIV RNA control plan of care, documented (HIV)"},{"system":"http://www.ama-assn.org/go/cpt","version":"2021","code":"3292F","display":"HIV testing ordered or documented and reviewed during the first or second prenatal visit (Pre-Cr)"},{"system":"http://www.ama-assn.org/go/cpt","version":"2021","code":"3490F","display":"History of AIDS-defining condition (HIV)"},{"system":"http://www.ama-assn.org/go/cpt","version":"2021","code":"3491F","display":"HIV indeterminate (infants of undetermined HIV status born of HIV-infected mothers) (HIV)"},{"system":"http://www.ama-assn.org/go/cpt","version":"2021","code":"3492F","display":"History of nadir CD4+ cell count \u003c350 cells/mm3 (HIV)"},{"system":"http://www.ama-assn.org/go/cpt","version":"2021","code":"3493F","display":"No history of nadir CD4+ cell count \u003c350 cells/mm3 and no history of AIDS-defining condition (HIV)"},{"system":"http://www.ama-assn.org/go/cpt","version":"2021","code":"3494F","display":"CD4+ cell count \u003c200 cells/mm3 (HIV)"},{"system":"http://www.ama-assn.org/go/cpt","version":"2021","code":"3495F","display":"CD4+ cell count 200 - 499 cells/mm3 (HIV)"},{"system":"http://www.ama-assn.org/go/cpt","version":"2021","code":"3496F","display":"CD4+ cell count \u003e/\u003d500 cells/mm3 (HIV)"},{"system":"http://www.ama-assn.org/go/cpt","version":"2021","code":"3497F","display":"CD4+ cell percentage \u003c15% (HIV)"},{"system":"http://www.ama-assn.org/go/cpt","version":"2021","code":"3498F","display":"CD4+ cell percentage \u003e/\u003d15% (HIV)"},{"system":"http://www.ama-assn.org/go/cpt","version":"2021","code":"3500F","display":"CD4+ cell count or CD4+ cell percentage documented as performed (HIV)"},{"system":"http://www.ama-assn.org/go/cpt","version":"2021","code":"3502F","display":"HIV RNA viral load below limits of quantification (HIV)"},{"system":"http://www.ama-assn.org/go/cpt","version":"2021","code":"3503F","display":"HIV RNA viral load not below limits of quantification (HIV)"},{"system":"http://www.ama-assn.org/go/cpt","version":"2021","code":"3510F","display":"Documentation that tuberculosis (TB) screening test performed and results interpreted (HIV) (IBD)"},{"system":"http://www.ama-assn.org/go/cpt","version":"2021","code":"3511F","display":"Chlamydia and gonorrhea screenings documented as performed (HIV)"},{"system":"http://www.ama-assn.org/go/cpt","version":"2021","code":"3512F","display":"Syphilis screening documented as performed (HIV)"},{"system":"http://www.ama-assn.org/go/cpt","version":"2021","code":"3513F","display":"Hepatitis B screening documented as performed (HIV)"},{"system":"http://www.ama-assn.org/go/cpt","version":"2021","code":"3514F","display":"Hepatitis C screening documented as performed (HIV)"},{"system":"http://www.ama-assn.org/go/cpt","version":"2021","code":"3515F","display":"Patient has documented immunity to Hepatitis C (HIV)"},{"system":"http://www.ama-assn.org/go/cpt","version":"2021","code":"4149F","display":"Hepatitis B vaccine injection administered or previously received (HEP-C, HIV) (IBD)"},{"system":"http://www.ama-assn.org/go/cpt","version":"2021","code":"4270F","display":"Patient receiving potent antiretroviral therapy for 6 months or longer (HIV)"},{"system":"http://www.ama-assn.org/go/cpt","version":"2021","code":"4271F","display":"Patient receiving potent antiretroviral therapy for less than 6 months or not receiving potent antiretroviral therapy (HIV)"},{"system":"http://www.ama-assn.org/go/cpt","version":"2021","code":"4274F","display":"Influenza immunization administered or previously received (HIV) (P-ESRD)"},{"system":"http://www.ama-assn.org/go/cpt","version":"2021","code":"4276F","display":"Potent antiretroviral therapy prescribed (HIV)"},{"system":"http://www.ama-assn.org/go/cpt","version":"2021","code":"4279F","display":"Pneumocystis jiroveci pneumonia prophylaxis prescribed (HIV)"},{"system":"http://www.ama-assn.org/go/cpt","version":"2021","code":"4280F","display":"Pneumocystis jiroveci pneumonia prophylaxis prescribed within 3 months of low CD4+ cell count or percentage (HIV)"},{"system":"http://www.ama-assn.org/go/cpt","version":"2021","code":"4290F","display":"Patient screened for injection drug use (HIV)"},{"system":"http://www.ama-assn.org/go/cpt","version":"2021","code":"4293F","display":"Patient screened for high-risk sexual behavior (HIV)"},{"system":"http://www.ama-assn.org/go/cpt","version":"2021","code":"86689","display":"Antibody; HTLV or HIV antibody, confirmatory test (eg, Western Blot)"},{"system":"http://www.ama-assn.org/go/cpt","version":"2021","code":"86701","display":"Antibody; HIV-1"},{"system":"http://www.ama-assn.org/go/cpt","version":"2021","code":"86702","display":"Antibody; HIV-2"},{"system":"http://www.ama-assn.org/go/cpt","version":"2021","code":"86703","display":"Antibody; HIV-1 and HIV-2, single result"},{"system":"http://www.ama-assn.org/go/cpt","version":"2021","code":"87389","display":"Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; HIV-1 antigen(s), with HIV-1 and HIV-2 antibodies, single result"},{"system":"http://www.ama-assn.org/go/cpt","version":"2021","code":"87390","display":"Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; HIV-1"},{"system":"http://www.ama-assn.org/go/cpt","version":"2021","code":"87391","display":"Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; HIV-2"},{"system":"http://www.ama-assn.org/go/cpt","version":"2021","code":"87534","display":"Infectious agent detection by nucleic acid (DNA or RNA); HIV-1, direct probe technique"},{"system":"http://www.ama-assn.org/go/cpt","version":"2021","code":"87535","display":"Infectious agent detection by nucleic acid (DNA or RNA); HIV-1, amplified probe technique, includes reverse transcription when performed"},{"system":"http://www.ama-assn.org/go/cpt","version":"2021","code":"87536","display":"Infectious agent detection by nucleic acid (DNA or RNA); HIV-1, quantification, includes reverse transcription when performed"},{"system":"http://www.ama-assn.org/go/cpt","version":"2021","code":"87537","display":"Infectious agent detection by nucleic acid (DNA or RNA); HIV-2, direct probe technique"},{"system":"http://www.ama-assn.org/go/cpt","version":"2021","code":"87538","display":"Infectious agent detection by nucleic acid (DNA or RNA); HIV-2, amplified probe technique, includes reverse transcription when performed"},{"system":"http://www.ama-assn.org/go/cpt","version":"2021","code":"87539","display":"Infectious agent detection by nucleic acid (DNA or RNA); HIV-2, quantification, includes reverse transcription when performed"},{"system":"http://www.ama-assn.org/go/cpt","version":"2021","code":"87900","display":"Infectious agent drug susceptibility phenotype prediction using regularly updated genotypic bioinformatics"},{"system":"http://www.ama-assn.org/go/cpt","version":"2021","code":"87901","display":"Infectious agent genotype analysis by nucleic acid (DNA or RNA); HIV-1, reverse transcriptase and protease regions"},{"system":"http://www.ama-assn.org/go/cpt","version":"2021","code":"87903","display":"Infectious agent phenotype analysis by nucleic acid (DNA or RNA) with drug resistance tissue culture analysis, HIV 1; first through 10 drugs tested"},{"system":"http://www.ama-assn.org/go/cpt","version":"2021","code":"87904","display":"Infectious agent phenotype analysis by nucleic acid (DNA or RNA) with drug resistance tissue culture analysis, HIV 1; each additional drug tested (List separately in addition to code for primary procedure)"},{"system":"http://www.ama-assn.org/go/cpt","version":"2021","code":"87906","display":"Infectious agent genotype analysis by nucleic acid (DNA or RNA); HIV-1, other region (eg, integrase, fusion)"}]}}